FDG-PET as a predictive biomarker
The mTOR (mammalian target of rapamycin) inhibitor, everolimus, affects tumor growth by targeting cellular metabolic proliferation pathways and delays renal cell carcinoma (RCC) progression.01/28/2014
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Kidney Cancer | Renal Cell Carcinoma | Urology & Nephrology